Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.62 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.62 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | GNPAT | O15228 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630365 | 1.00 | ERAP2 (0.62) | ERAP2LNPEPMMP2GNPATOPRK1 | |
| SCHEMBL30915103 | 0.97 | GNPAT (0.62) | ERAP2LNPEPMMP2GNPATOPRK1 | |
| SCHEMBL30051985 | 0.97 | GNPAT (0.62) | ERAP2LNPEPMMP2GNPATOPRK1 | |
| SCHEMBL29372662 | 0.97 | ERAP2 (0.65) | ERAP2LNPEPMMP2GNPATOPRK1 | |
| SCHEMBL29382413 | 0.97 | ERAP2 (0.65) | ERAP2LNPEPMMP2GNPATOPRK1 | |
| SCHEMBL9747671 | 0.97 | ERAP2 (0.65) | ERAP2LNPEPMMP2GNPATOPRK1 | |
| SCHEMBL1711485 | 0.97 | ERAP2 (0.65) | ERAP2LNPEPMMP2GNPATOPRK1 | |
| SCHEMBL28540087 | 0.97 | ERAP2 (0.65) | ERAP2LNPEPMMP2GNPATOPRK1 | |
| SCHEMBL170652 | 0.97 | ERAP2 (0.65) | ERAP2LNPEPMMP2GNPATOPRK1 | |
| SCHEMBL30463392 | 0.96 | ERAP2 (0.59) | ERAP2LNPEPMMP2GNPATOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119080883-A | Antibacterial peptide and application thereof | 合肥科生景肽生物科技有限公司 | 2024-12-06 | — | — | CN | claimed |
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-03-03 | — | — | US | claimed |
| US-20250249113-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING SA (CH) | 2025-08-07 | — | — | US | disclosed |
| CN-119255824-A | Ligand-drug conjugates with improved pharmacokinetic and drug release profiles | 德比欧药物研究有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119080883-A | Antibacterial peptide and application thereof | 合肥科生景肽生物科技有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-03-03 | — | — | US | disclosed |
| EP-1358342-A2 | RETROVIRAL VECTORS FOR TRANSDUCTION INTO QUIESCENT CELLS AND PACKAGING SYSTEMS FOR THEM | The Children's Medical Center Corporation (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002059338-A2 | RETROVIRAL VECTORS FOR TRANSDUCTION INTO QUIESCENT CELLS AND PACKAGING SYSTEMS FOR THEM | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | CTSB, CTSE, CTSV | ERAP2 46/4885LNPEP 13/4885MMP2 116/4885 |
| US-20250249113-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | FCER2, FCGR2A, FCGR1A | ERAP2 830/4885LNPEP 150/4885MMP2 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.